<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712881</url>
  </required_header>
  <id_info>
    <org_study_id>C19562/2037</org_study_id>
    <secondary_id>2008-000709-12</secondary_id>
    <nct_id>NCT00712881</nct_id>
  </id_info>
  <brief_title>Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer</brief_title>
  <official_title>Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of treatment with MYOCET® in combination with
      Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles,
      in women with stage II or III breast cancer whose tumour overexpresses the HER2 gene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicentre, open-label, randomized, Phase 2 study to evaluate the efficacy and safety of
      treatment with MYOCET® in combination with cyclophosphamide and trastuzumab versus free
      doxorubicin in combination with cyclophosphamide, each followed by docetaxel and trastuzumab,
      in women with stage II or III breast cancer whose tumour overexpresses the HER2 gene.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (pCR) in breast, upon histologic examination.</measure>
    <time_frame>24 weeks of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the proportion of patients who achieve an objective response [Complete Response (CR) or Partial Response (PR)] as defined by WHO guidelines.</measure>
    <time_frame>24 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of class III or IV (NYHA) congestive heart failure (CHF) at any time during the study.</measure>
    <time_frame>24 weeks +</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction from baseline left ventricular ejection fraction (LVEF) ﻿at any time during the study.</measure>
    <time_frame>24 weeks +</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events throughout the study, characterized by NCI CTCAE version 3 guidelines.</measure>
    <time_frame>24 weeks +</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the proportion of patients with progression-free survival (PFS) 5 years after being randomly assigned to treatment.</measure>
    <time_frame>5 year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the proportion of patients who achieve pathological complete response (pCR) in breast and axillary lymph node.</measure>
    <time_frame>24 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the proportion of patients with conservative surgery.</measure>
    <time_frame>24 weeks +</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>(1) Investigational Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>(2) Comparison Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles</intervention_name>
    <description>MYOCET® (60 mg/m2) and cyclophosphamide (600 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (6 mg/kg) once every 3 weeks for 4 cycles (MCH→TH).</description>
    <arm_group_label>(1) Investigational Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles</intervention_name>
    <description>Free doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) once every 3 weeks for 4 cycles (AC→TH).</description>
    <arm_group_label>(2) Comparison Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Treatment-naive patients with stage II or III invasive breast cancer (proven
             histologically/cytologically) and with tests showing an overexpressing of human
             epidermal growth factor receptor 2 (HER2).

          -  Patients have at least one bidimensionally measurable lesion according to the WHO
             criteria.

          -  The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0
             or 1.

          -  The patient has an LVEF of at least 55% as assessed by multiple-gated acquisition
             (MUGA) scan (preferred) or echocardiography.

          -  The patient has hematology and serum chemistry laboratory test results within specific
             protocol-defined ranges.

          -  Women of childbearing potential must use a medically accepted method of contraception
             and must agree to continue use of this method for the duration of the treatment period
             and for 6 months after the last administration of study drug.

        Main Exclusion Criteria:

        The patient:

          -  Has received previous cancer therapy for breast cancer.

          -  Has any history of CHF, angina pectoris, or myocardial infarction.

          -  Has uncontrolled hypertension.

          -  Has infection, peptic ulcer, or unstable diabetes mellitus.

          -  Has been treated with live virus vaccines within 8 weeks before the first
             administration of study drug.

          -  Has impaired hepatic or renal function.

          -  Is a pregnant or lactating woman. (Any women becoming pregnant during the study will
             be withdrawn from the study.)

          -  Has used an investigational drug within one month before the screening visit.

          -  Has a known hypersensitivity to any of the study drugs or to their active ingredients.

          -  Has an inflammatory breast cancer.

          -  Has had any other malignancies within five years (except for adequately treated
             carcinoma in situ of the cervix or basal or squamous cell skin cancer).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 16</name>
      <address>
        <city>Kufstein</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 15</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 29</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 4</name>
      <address>
        <city>Clichy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 33</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8</name>
      <address>
        <city>Vandoeuvre-Les-Nancy CEDEX</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 25</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34</name>
      <address>
        <city>Lorrach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 27</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 20</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 23</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 21</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 26</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 2</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2008</study_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

